SONN Sonnet BioTherapeutics Holdings, Inc. Stock Quote

SONN [NASD]

Sonnet BioTherapeutics Holdings, Inc.

Index	-	P/E	-	EPS (ttm)	-0.69	Insider Own	1.30%	Shs Outstand	63.91M	Perf Week	-5.00%
Market Cap	17.00M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	0.00%	Shs Float	58.66M	Perf Month	4.35%
Income	-27.50M	PEG	-	EPS next Q	-0.10	Inst Own	9.90%	Short Float	3.63%	Perf Quarter	-29.26%
Sales	0.70M	P/S	24.29	EPS this Y	85.40%	Inst Trans	45.38%	Short Ratio	1.05	Perf Half Y	-37.04%
Book/sh	0.14	P/B	1.90	EPS next Y	15.20%	ROA	-152.70%	Target Price	2.25	Perf Year	-83.06%
Cash/sh	0.21	P/C	1.25	EPS next 5Y	-	ROE	-226.40%	52W Range	0.23 - 2.07	Perf YTD	-35.61%
Dividend	-	P/FCF	-	EPS past 5Y	54.30%	ROI	-	52W High	-87.15%	Beta	0.59
Dividend %	-	Quick Ratio	2.30	Sales past 5Y	-59.00%	Gross Margin	-	52W Low	16.67%	ATR	0.02
Employees	9	Current Ratio	2.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.92	Volatility	7.49% 8.92%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	57.70%	Profit Margin	-	Rel Volume	0.20	Prev Close	0.28
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.03M	Price	0.27
Recom	1.50	SMA20	1.66%	SMA50	-2.49%	SMA200	-36.59%	Volume	410,769	Change	-5.00%

Jun-09-22 07:00AM	Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition ACCESSWIRE +23.00%
Jun-02-22 09:25AM	Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum ACCESSWIRE
May-10-22 08:15AM	Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update ACCESSWIRE
Apr-13-22 07:00AM	Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors ACCESSWIRE -14.50%
Apr-08-22 01:05PM	Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting ACCESSWIRE
Mar-16-22 07:00AM	Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors ACCESSWIRE +86.73%
Feb-09-22 06:30AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting ACCESSWIRE
Feb-08-22 07:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update ACCESSWIRE
Dec-20-21 12:58PM	We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate Simply Wall St.
Dec-17-21 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update ACCESSWIRE -7.39%
Aug-30-21 04:01PM	Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) ACCESSWIRE
Aug-19-21 09:35PM	Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering ACCESSWIRE +63.74%
Aug-16-21 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update ACCESSWIRE -9.96%
Jun-14-21 07:45AM	Sonnet BioTherapeutics Announces Change in Date of Annual Meeting ACCESSWIRE
Jun-08-21 04:30PM	Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology ACCESSWIRE
May-17-21 07:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update ACCESSWIRE
May-10-21 06:30AM	Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP) ACCESSWIRE
May-03-21 06:00AM	Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics ACCESSWIRE -12.66%
Mar-29-21 04:30PM	Sonnet BioTherapeutics Provides 2021 Business Update ACCESSWIRE
Mar-22-21 07:00AM	Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations ACCESSWIRE
Feb-16-21 08:10AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update ACCESSWIRE
Feb-03-21 06:30AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting ACCESSWIRE
Feb-01-21 06:30AM	Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates ACCESSWIRE
Jan-25-21 06:30AM	Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080 ACCESSWIRE
Dec-17-20 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update ACCESSWIRE -6.02%
Nov-30-20 08:30AM	Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010 ACCESSWIRE
Sep-01-20 08:30AM	Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB) ACCESSWIRE
Aug-25-20 07:30AM	Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants ACCESSWIRE -18.97%
Aug-24-20 07:37AM	Sonnet Bio Spikes 70% In Pre-Market On FDA Covid-19 Plasma Nod SmarterAnalyst +48.29%
Aug-14-20 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update ACCESSWIRE
Aug-04-20 07:35AM	Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million ACCESSWIRE
07:30AM	Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics ACCESSWIRE
Jul-20-20 07:30AM	Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12 ACCESSWIRE
Jul-15-20 07:30AM	Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference ACCESSWIRE +10.03%
May-18-20 07:30AM	Sonnet BioTherapeutics Holdings Provides Business and Earnings Update ACCESSWIRE
Apr-06-20 07:30AM	Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board ACCESSWIRE

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience